selected publications
-
academic article
- Performance Metrics of Substance Use Disorder Care Among Medicaid Enrollees in New York, New York.. JAMA health forum. 3:-. 2022
- Marijuana use and major depressive disorder are additively associated with reduced verbal learning and altered cortical thickness.. Cognitive, affective & behavioral neuroscience. 19:1047-1058. 2019
- A placebo-controlled randomized trial of D-cycloserine augmentation of cue exposure therapy for smoking cessation.. Cognitive Behaviour Therapy. 48:65-76. 2018
- Improved Depressive Symptoms in Adults with Schizophrenia During a Smoking Cessation Attempt with Varenicline and Behavioral Therapy.. Journal of Dual Diagnosis. 13:168-178. 2017
- Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy.. Addictive Behaviors. 89-95. 2017
- Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder.. Schizophrenia Research. 124-129. 2016
- Early onset marijuana use is associated with learning inefficiencies.. Neuropsychology. 30:405-15. 2016
- Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial.. Journal of Clinical Psychiatry. 77:e320-6. 2016
- Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.. JAMA. 311:145-54. 2014
- Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.. Psychopharmacology. 231:765-75. 2013